TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
Open Access
- 14 October 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e109924
Abstract
The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information. We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 mutations and 17p loss. The majority of cases were profiled by copy number (n = 32) and gene expression (n = 36) arrays. TP53 mutational status was correlated with patient event-free and overall survival, genomic copy number instability and gene expression profiling. From the 40 cases, 22 (55%) had TP53 mutations (2 detected only after deep-sequencing), 20 of which also had 17p loss (91%); 18 (45%) cases had no detectable mutation but three had 17p loss. Tumours with TP53 mutations and/or 17p loss (n = 25) had an increased risk of recurrence as a first event (p = 0.03, hazard ratio (HR), 3.89; 95% confidence interval (CI), 1.26–16.0) and death (p = 0.04, HR, 4.95; 95% CI, 1.36–31.7) compared to tumours lacking TP53 abnormalities. DAWT carrying TP53 mutations showed increased copy number alterations compared to those with wild-type, suggesting a more unstable genome (p = 0.03). These tumours showed deregulation of genes associated with cell cycle and DNA repair biological processes. This study provides evidence that TP53 mutational analysis improves risk stratification in DAWT. This requires validation in an independent cohort before clinical use as a biomarker.Keywords
This publication has 47 references indexed in Scilit:
- Circular binary segmentation for the analysis of array-based DNA copy number dataBiostatistics, 2004
- Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trialThe Lancet, 2004
- Doxorubicin for favorable histology, Stage II–III Wilms tumorCancer, 2004
- The Treatment of Stages I–IV Favorable Histology Wilms' TumorJournal of Clinical Oncology, 2004
- The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instabilityProceedings of the National Academy of Sciences, 2003
- Clinical and biologic significance of nuclear unrest in Wilms tumorCancer, 2003
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002
- Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutationsNature Genetics, 1994
- Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.1994
- Histopathology and prognosis of Wilms tumorResults from the first national wilms' tumor studyCancer, 1978